This study is testing how different types of protein - from red meat, legumes (like lentils and beans), or a mix of both - affect muscle strength, body composition, and metabolic health in older adults with obesity who are also at risk for sarcopenia (loss of muscle mass and function). Participants will follow a personalized weight loss diet with one high-protein meal each day that includes either red meat, legumes, or both, along with a home-based strength training program. The study will last three months and will include health assessments such as blood tests, muscle and fat measurements, and physical function tests. The goal is to find out which type of protein source is most helpful for improving strength, reducing body fat, and supporting healthy aging.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
180
Participants receive a hypocaloric, high-protein diet primarily based on legumes (e.g., lentils, beans, peas) designed to meet protein goals (\~2g/kg body weight). Diet is combined with a structured home-based resistance training program performed 3 times per week for 12 weeks. The exercise includes progressive resistance exercises focusing on major muscle groups using body weight and resistance bands.
Participants follow a hypocaloric, high-protein diet emphasizing animal-based protein sources, mainly lean meats, to achieve \~2g/kg body weight protein intake. This dietary intervention is combined with a 12-week, home-based resistance training protocol, performed thrice weekly, targeting major muscle groups with progressive overload using body weight and resistance bands.
Participants adhere to a hypocaloric, high-protein diet combining both legumes and lean meats as protein sources to reach \~2g/kg body weight. The dietary plan is paired with a 12-week home-based resistance training program, performed 3 times per week, emphasizing progressive resistance exercises for all major muscle groups using body weight and resistance bands.
Tel Aviv Sourasky Medical Center
Tel Aviv, Tel Aviv, Israel
MetaboAnabolic Score
The MetaboAnabolic Score is a composite outcome designed to assess the intervention's efficacy in addressing sarcopenic obesity from both metabolic and functional perspectives. The score includes 10 variables: five metabolic (body fat percentage, intramuscular adipose tissue \[IMAT\], visceral fat area, blood pressure, and triglyceride or LDL levels) and five functional (leg muscle/lean mass, leg and arm strength, Timed Up and Go \[TUG\], and 2-minute walk test). A clinically meaningful threshold is defined for each variable based on scientific literature or expected changes from the hypocaloric intervention. One point is awarded for each variable that meets or exceeds the threshold, resulting in a total score ranging from 0 to 10. A higher score reflects greater overall improvement.
Time frame: Baseline, Week 6, Week 12
Functional Performance Tests (TUG, STS, Gait, Strength)
TUG, 2-minute walk, 30s sit-to-stand, one-leg stand (gait, endurance, stability). Muscle strength of upper and lower limbs measured via handheld dynamometers. Gait variability and balance measured using Mobility Lab (OPAL) sensors
Time frame: Baseline, Week 6, Week 12
C-Reactive Protein (CRP) Levels
High-sensitivity CRP will be measured via blood samples to assess systemic inflammation. CRP is a biomarker associated with metabolic and cardiovascular risk.
Time frame: Baseline, Week 6, Week 12
Lipid Profile (Triglycerides, LDL, HDL, Total Cholesterol)
Fasting blood samples will be used to assess lipid parameters including triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol. These are key indicators of cardiovascular and metabolic health. Changes will be compared between intervention groups.
Time frame: Baseline, Week 6, Week 12
Glycemic Control (Fasting Glucose, Insulin, HOMA-IR)
Fasting glucose and insulin levels will be used to evaluate glycemic control and insulin sensitivity. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) will be calculated.
Time frame: Baseline, Week 6, Week 12
Resting Metabolic Rate (RMR)
RMR will be measured via indirect calorimetry under standardized fasting and resting conditions. It reflects basal energy expenditure and can indicate metabolic adaptation or dysfunction. Changes will be analyzed in the context of body composition shifts.
Time frame: Baseline and Week 12
Body Composition (Lean Mass, Fat Mass, Visceral Fat Area)
Dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis will be used to assess lean body mass, total fat mass, and visceral fat area. Changes in these components will provide insight into the impact of the dietary interventions on sarcopenic obesity.
Time frame: Baseline, Week 6, Week 12
Muscle Quality Indices (Glycogen and Intramuscular Fat Levels)
Quantitative ultrasound will assess skeletal muscle glycogen storage and intramuscular fat infiltration (IMAT). This will be assessed by ultrasound of rectus femoris with MuscleSound® software, which analyzes cross-sectional area, thickness, and composition. These indices serve as biomarkers of muscle health and metabolic quality, with changes reflecting diet and exercise response.
Time frame: Baseline, Week 6, Week 12
Ambulatory Blood Pressure (24-hour monitoring)
Blood pressure will be monitored over 24 hours using a validated automatic ambulatory device to capture daily fluctuations.
Time frame: Baseline, Week 6, Week 12
Quality of Life (SF-12)
Health-related quality of life assessed using the validated SF-12 questionnaire, translated and culturally adapted to Hebrew.
Time frame: Baseline, Week 6, Week 12
Hormonal Markers (Testosterone, IGF-1, Vitamin D)
Serum levels of testosterone (bioavailable and free), IGF-1, and 25-hydroxyvitamin D will be measured using standard clinical protocols.
Time frame: Baseline, Week 6, Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.